Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

BioQ Pharma expands US license and supply deal with Sandoz BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready‐to‐use BioQ Pharma infusion pharmaceutical in the US.
Contract Research & Services > Contract Services > News
AstraZeneca sells US rights to gout drug Zurampic to Ironwood Pharmaceuticals By PBR Staff Writer
AstraZeneca is selling the US rights to its gout treatment Zurampic (lesinurad) to Ironwood Pharmaceuticals.
Contract Research & Services > Contract Services > News Aytu BioScience buys US commercial rights to Natesto Nasal Gel Aytu BioScience has executed a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals for the U.S. commercial rights to Natesto (testosterone) Nasal Gel.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Immune Therapeutics signs binding LoI to acquire Chinese CAR-T technology and clinical data
Immune Therapeutics has signed a binding Letter of Intent (LoI) to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data of the aforementioned therapies from Super-T Cell Cancer Company ("STCC") a newly formed corporation.
Contract Research & Services > Contract Services > News
OncBioMune signs deal with Vitel to form JV to develop cancer therapies
OncBioMune Pharmaceuticals has signed a contract to form a Joint Venture (JV) with Vitel Laboratorios to develop and commercializie OncBioMune's portfolio of innovative cancer therapies in Mexico and Latin America.
Contract Research & Services > Contract Services > News
Evotec, Pierre Fabre sign multi-year compound management deal
Evotec has signed a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.
Contract Research & Services > Contract Services > News
Enumeral, Pieris Pharmaceuticals sign license and transfer agreement
Enumeral Biomedical has entered into a License and Transfer Agreement with Pieris Pharmaceuticals and Pieris Pharmaceuticals (collectively, Pieris).
Contract Research & Services > Contract Services > News
NewLink Genetics secures $2.8m award from DTRA to develop multivalent filovirus vaccine
The Defense Threat Reduction Agency (DTRA) of the United States Department of Defense has awarded a subsidiary of NewLink Genetics a $2.8m base contract with potential future options totaling $6.3m to support the development of vaccines against filovirus species including Marburg and Ebola Sudan viruses, which could be combined with Ebola Zaire virus in a multivalent vaccine formulation or vaccination schedule.
Contract Research & Services > Contract Services > News
Akari Therapeutics, XL-protein sign license deal to develop long acting version of Coversin
Akari Therapeutics and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement.
Contract Research & Services > Contract Services > News
Aires Pharmaceuticals inks deal with Duke University for Phase 2 study of AIR001 in HFpEF patients
Mast Therapeutics' subsidiary, Aires Pharmaceuticals, has entered into an agreement with Duke University to provide support for a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study of the Company's product candidate AIR001 in patients with heart failure with preserved ejection fraction (HFpEF).
Contract Research & Services > Contract Services > News
Oncternal Therapeutics secures worldwide license to ROR1 antibody from UC San Diego
Oncternal Therapeutics has received an exclusive worldwide license to develop and commercialize antibodies and antibody-related binding agents recognizing Receptor-tyrosine kinase-like orphan receptor 1 (ROR1) from University of California San Diego.
Contract Research & Services > Contract Services > News
EUSA Pharma acquires global rights to Arcoral Tab from Arcoral Pharma
EUSA Pharma has acquired the global rights to a next generation formulation of EUSA's current Caphosol product from Arcoral Pharma.
Contract Research & Services > Contract Services > News
Tobira Therapeutics, Dong-A ST sign license agreements for Evogliptin and Cenicriviroc
Tobira Therapeutics and Dong-A ST Co. have entered into two separate licensing agreements.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests